ImmuneOnco Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $89M
Latest Deal Amount
  • Investors
  • 13

ImmuneOnco General Information

Description

Researcher and developer of tumor immunotherapy designed to reverse cancer cell-induced immune inhibition and actively eradicate cancer cells. The company harnesses two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task, enabling tumor patients to receive more effective treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • Room 502, Lane 1043, Harley Road
  • Pudong New District
  • Shanghai
  • China
+86 021 0000 0000

ImmuneOnco Timeline

2018201920202021
Financing RoundFinancing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmuneOnco Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series C) 21-Mar-2021 $89M 00000 00000 Completed Clinical Trials - Phase 1
7. Early Stage VC (Series B) 10-Oct-2020 0000 000.00 00000 Completed Clinical Trials - Phase 1
6. Early Stage VC 14-Jul-2020 00.00 000.00 00000 Completed Clinical Trials - Phase 1
5. Early Stage VC 20-Feb-2020 00.000 000.00 00000 Completed Pre-Clinical Trials
4. Early Stage VC (Series A) 11-Apr-2018 000.00 000.00 Completed Pre-Clinical Trials
3. Grant 21-Dec-2017 00000 00.000 Completed Product Development
2. Early Stage VC 08-Dec-2017 $2.31M Completed Product Development
1. Early Stage VC 11-Apr-2016 $2.31M $2.31M 0000 Completed Startup
To view ImmuneOnco’s complete valuation and funding history, request access »

ImmuneOnco Executive Team (3)

Name Title Board Seat Contact Info
Wenzhi Tian MD Chairman, Chief Executive Officer and Co-Founder
Song Li Board Member & Senior Director
Heming He MD Chief Medical Officer
To view ImmuneOnco’s complete executive team members history, request access »

ImmuneOnco Board Members (5)

Name Representing Role Since
Song Li ImmuneOnco Board Member & Senior Director 000 0000
Wenzhi Tian MD ImmuneOnco Chairman, Chief Executive Officer and Co-Founder 000 0000
Zhenping Zhu MD ImmuneOnco Board Member 000 0000
You’re viewing 3 of 5 board members. Get the full list »

ImmuneOnco Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Greater Bay Area Homeland Venture Capital Minority 000 0000 000000 0
Shanghai Science and Technology Innovation Center Fund of Funds Minority 000 0000 000000 0
Lilly Asia Ventures Venture Capital Minority 000 0000 000000 0
LYFE Capital Venture Capital Minority 000 0000 000000 0
Million Capital PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »